Discovery Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Nogi-machi, Shimotsuga-gun, Tochigi, Japan.
Bioorg Med Chem Lett. 2013 Oct 1;23(19):5311-6. doi: 10.1016/j.bmcl.2013.07.069. Epub 2013 Aug 8.
We previously identified KCA-1490 [(-)-6-(7-methoxy-2-trifluoromethyl-pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-3-(2H)-pyridazinone], a dual PDE3/4 inhibitor. In the present study, we found highly potent selective PDE4 inhibitors derived from the structure of KCA-1490. Among them, N-(3,5-dichloropyridin-4-yl)-7-methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridine-4-carboxamide (2a) had good anti-inflammatory effects in an animal model.
我们之前鉴定出 KCA-1490 [(-)-6-(7-甲氧基-2-三氟甲基吡唑并[1,5-a]嘧啶-4-基)-5-甲基-4,5-二氢-3(2H)-哒嗪酮],一种双重 PDE3/4 抑制剂。在本研究中,我们从 KCA-1490 的结构中发现了高效选择性 PDE4 抑制剂。其中,N-(3,5-二氯吡啶-4-基)-7-甲氧基-2-(三氟甲基)吡唑并[1,5-a]嘧啶-4-甲酰胺(2a)在动物模型中具有良好的抗炎作用。